Toggle navigation
About Us
Business Areas
R & D
Manufacturing
Beyond Business
Investors
Careers
Contact Us
Investors
Investors > FY 2021-22
Overview
Chairman's Statement
Shareholder Information
Policies or Statutory Documents
IEPF
Debentures
Amalgamation
MOA/AOA
Procedure for Dematerialisation of Shares
Archives
Credit Ratings
CSR
AGM Transcript
Annual Return
Disclosures under Regulation 46 and 62 of SEBI LODR
Financial
2022-23
2021-22
2020-21
2019-20
2018-19
2017-18
2016-17
2015-16
2014-15
2013-14
2012-13
2011-12
Investors > FY 2021-22
1. Annual Report
Annual Report 2021-22
Torrent Pharma Inc
Torrent Do Brasil Ltda
Heumann Pharma GmbH & Co
Heunet Pharma GmbH
Torrent Pharma GmbH
Torrent Pharma Philippines Inc
Zao Torrent Pharma
Torrent Pharma (UK) Ltd
Laboratorios Torrent, S.A. de C.V
Laboratories Torrent Malaysia Sdn. Bhd
Torrent Pharma (Thailand) Co.Ltd
Torrent Australasia Pty. Ltd
Torrent Pharma (Malta) Limited
TPL (Malta) Ltd_31-03-2022
2. Intimation to Stock Exchange
Transcript of Conference call with Analysts / Investors on Audited Financial Results for the quarter and year ended 31st March, 2022
Secretarial Compliance Report for the year ended 31st March, 2022
Intimation of Record Date for the purpose of payment of final dividend for the year 2021-22
Intimation for Presentation to analysts on audited financial result for the quarter and year ended 31st March, 2022
Compliance as per Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation for Concall with Investors / Analyst Q4_2021-22
Shareholding Pattern Q4
Intimation for Trading Window Closure
Newspaper Advertisement of Financial Result for Q3 2021-22
Intimation for Presentation to analysts on audited financial result for the quarter and half year ended 31st December, 2021
Shareholding Pattern Q3
Intimation for Concall with Investors / Analyst Q3_2021-22
Intimation of Board Meeting dated 25-01-2022
Intimation of Record Date_Interim Dividend
Intimation for Trading Window Closure
Updated Press Release – Torrent Pharma to launch Molnupiravir under the brand name Molnutor® in India
Press Release – Torrent Pharma introduces Molnupiravir under the brand name Molnutor® in India
Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.pdf
Partial_Redemption_of_Non-Convertible_Debentures_issued_under_ISIN_INE685A07082.pdf
USFDA inspection at Torrent’s manufacturing facility at Levittown, Pennsylvania, USA
Redemption of Non-Convertible Debentures issued under ISIN:INE685A07066
Intimation of Schedule of Investors Meet_03-12-2021
Intimation of Schedule of Investors Meet_12-11-2021_15-11-2021 & 16-11-2021
Intimation of Schedule of Investors Meet_17-11-2021
Newspaper Advertisement of Financial Result for Q2 2021-22
Intimation of Schedule of Investors Meet_15-11-2021
Compliance as per Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation for Presentation to analysts on audited financial result for the quarter and half year ended 30th September, 2021
Intimation for Concall with Investors / Analyst Q2_2021-22
Shareholding Pattern Q2
Intimation for Concall with Investors/Analyst Q2_2021-22
Intimation of the Board Meeting dated 26-10-2021
Intimation for Trading Window Closure
Intimation of Schedule of Investors Meet_28-09-2021
Intimation of Schedule of Investors Meet_27-09-2021
Intimation of Schedule of Investors Meet_14-09-2021
Intimation of Credit Rating
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Newspaper Advertisement of financial result for Q1 2021-22
Intimation for Presentation to analysts on audited financial result for the quarter ended 30th June, 2021
Voting Results and Scrutinizer’s Report_AGM dated 27-07-2021
Proceedings of 48th Annual General Meeting of the Company held on 27th July, 2021
Shareholding Pattern Q1
Intimation for Concall with Investors Analyst Q1_2021-22
Intimation of the board meeting dated 27-07-2021
Newspaper advertisement in respect of Annual General Meeting and E-Voting Procedure
Press Release
Newspaper advertisement regarding Intimation of the 48th AGM of the Company through VC / OAVM facility
Intimation for Trading Window Closure
Secretarial Compliance Report for the year ended 31st March, 2021
Intimation of Redemption of Commercial Papers
Intimation of Schedule of Investors Meet_09-06-2021
Compliance as per Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for half year ended 31st March, 2021
Intimation of Schedule of Investors Meet 03-06-2021
Intimation of Schedule of Investors Meet_27-05-2021
Press Release
Intimation of Credit Rating
Newspaper advertisement for BM notice_18-05-2021
Intimation of Board Meeting dated 18-05-2021
Payment of Interest & Partial Redemption of Secured Redeemable Non-Convertible Debenture issued under ISIN:INE685A07108
Partial Redemption of Non-Convertible Debentures issued under ISIN: INE685A07108
3. Quarterly Results
Q1 21-22
Q2 21-22
Q3 21-22
Q4 21-22
Newspaper Advertisement Results Q1
Q1 FY22 Earnings Call Transcript
Press Release
Standalone Result
Consolidated Result
Newspaper Advertisement Results Q2
FY22 Earnings Call Transcript
Press Release Q2 FY22 results
Q2 Consolidated Result
Q2 Standalone Result
Newspaper Advertisement Results Q3
Q3 FY22 Earnings call Transcript
Press Release Q3 FY22 results
Consolidated Result
Standalone Result
Newspaper Advertisement Results Q4
Q4 FY22 Earnings Call Transcript
Audio Recording of conference call on Audited Financial Results for the quarter and year ended March 31, 2022
Press Release Q4 FY22 results
Consolidated Result
Standalone Result
4. Shareholder Communication Tax on Dividend
Shareholder’s Communication – Tax on Final Dividend
Shareholder’s Communication – Tax on Interim Dividend
Details of Nodal Officer
Name
: Chintan Trivedi
Designation
: Company Secretary
E-mail Id
: investorservices@torrentpharma.com
IEPF Authority - Refund web page
IEPF Authority - Refund web page >>